Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (ACTRN12625001087448) titled 'Exploring how ketamine affects the brain function in people with difficult-to-treat depression' on Oct. 7.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Other
Type of endpoint: Efficacy
Primary Sponsor: The University of Melbourne
Condition:
Major Depressive Disorder
Major Depressive Disorder
Mental Health - Depression
Intervention:
Participants with difficult-to-treat depression will receive a single subcutaneous injection of 0.75mg/kg ketamine. The intervention is administered under medical supervision in...